For October 2023, we have the Human Epidermal growth factor Receptor 3 (HER3) as the 'Clovertex Drug Target of the Month'. In a busy month for the antibody-drug conjugate (ADC) field, the spotlight falls on HER3, a member of the EGFR family, pivotal in cancer progression pathways.
HER3's prominence is underscored by Merck & Co. and Daiichi Sankyo’s collaboration, potentially worth up to $22 billion, to co-develop three ADC candidates targeting cancers. Patritumab deruxtecan (HER3-DXd), a frontrunner, is tailored for EGFR-mutated non-small cell lung cancer (NSCLC) post-progression on prior therapies. The FDA granted its Breakthrough Therapy Designation to patritumab deruxtecan in December 2021 and the companies plan to submit a biologics license application (BLA) for patritumab deruxtecan to the FDA by the end of March 2024. The protein model rendering features the cryo-EM structure of the HER2/HER3/NRG1b Heterodimer Extracellular Domain bound to Trastuzumab Fab (PDB 7MN8).
Clovertex is an industry leader specializing in meeting the scientific IT needs of pharmaceutical companies, with a robust focus on cloud-based or on-premises cryo-EM processing. As an Advanced Tier Services Partner with Amazon Web Services (AWS), Clovertex leverages its comprehensive expertise to architect, build, automate, and manage software applications designed to meet specific research needs. Our all-encompassing solutions are meticulously tailored to streamline the complex processes associated with pharmaceutical research, underscoring our commitment to innovation, efficiency, and customer satisfaction. By integrating state-of-the-art technology with deep scientific understanding, Clovertex paves the way in optimizing the intersection of information technology and pharmaceutical development.
1. Merck, Daiichi Sankyo Ink Up-to-$22B Cancer ADC Collaboration
2. Clovertex website